Automated Hematology Analyzer Quantifies Immature Granulocytes
|
By LabMedica International staff writers Posted on 05 May 2010 |
|
An automated hematology analyzer's immature granulocyte (IG) parameter provides the effective detection and quantification of circulating immature granulocytes that may be used by physicians as an early indicator of acute infection, inflammatory response, or myeloproliferative disorder.
Sysmex America, Inc. (Mundelein, IL, USA), a medical diagnostic instrument manufacturer and information systems developer, announced that its Sysmex XT-4000i automated hematology analyzer has been cleared by the U.S. Food and Drug Administration (FDA). The Sysmex XT-4000i provides 34 parameters, including the advanced clinical parameters, IG and RET-He (reticulocyte hemoglobin equivalent), and a body fluid specific mode. It utilizes Sysmex's patented fluorescent flow cytometry and advanced cell counting methods to deliver rapid, reliable results essential in patient diagnosis and therapeutic monitoring.
"With FDA's clearance of the Sysmex XT-4000i, we are truly in a unique position to offer a portfolio of hematology products that support the needs of small clinics to high-volume clinical laboratories in every sized hospital or integrated delivery network in the nation. Additionally, the Sysmex XT-4000i offers the reliability and standardization of Sysmex's patented flow cytometry technology platform, thereby enhancing efficiency and improving productivity without sacrificing quality or accuracy,” said John Kershaw, president and CEO, Sysmex America.
The system's RET-He parameter, which quantifies the hemoglobin content of reticulocytes, is an established parameter in the U.S. National Kidney Foundation's KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines for assessing the initial iron status of patients with chronic kidney disease on hemodialysis as well as intravenous iron replacement in these patients.
Sysmex America, the U.S. headquarters of Sysmex Corp. (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation, and information systems. Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.
Related Links:
Sysmex America
Sysmex America, Inc. (Mundelein, IL, USA), a medical diagnostic instrument manufacturer and information systems developer, announced that its Sysmex XT-4000i automated hematology analyzer has been cleared by the U.S. Food and Drug Administration (FDA). The Sysmex XT-4000i provides 34 parameters, including the advanced clinical parameters, IG and RET-He (reticulocyte hemoglobin equivalent), and a body fluid specific mode. It utilizes Sysmex's patented fluorescent flow cytometry and advanced cell counting methods to deliver rapid, reliable results essential in patient diagnosis and therapeutic monitoring.
"With FDA's clearance of the Sysmex XT-4000i, we are truly in a unique position to offer a portfolio of hematology products that support the needs of small clinics to high-volume clinical laboratories in every sized hospital or integrated delivery network in the nation. Additionally, the Sysmex XT-4000i offers the reliability and standardization of Sysmex's patented flow cytometry technology platform, thereby enhancing efficiency and improving productivity without sacrificing quality or accuracy,” said John Kershaw, president and CEO, Sysmex America.
The system's RET-He parameter, which quantifies the hemoglobin content of reticulocytes, is an established parameter in the U.S. National Kidney Foundation's KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines for assessing the initial iron status of patients with chronic kidney disease on hemodialysis as well as intravenous iron replacement in these patients.
Sysmex America, the U.S. headquarters of Sysmex Corp. (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation, and information systems. Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.
Related Links:
Sysmex America
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Clinical Chemistry System
P780
Hemodynamic System Monitor
OptoMonitor
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Industry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more